Editorial hapabapa/iStock via Getty Images
Novo Nordisk (NOVO) is petitioning the US Food and Drug Administration (FDA) to exclude the diabetes drug liraglutide, also known as Victoza, from the list of approved drugs for compounding.
In a citizen petition posted on Rules.gov, Novo Nordisk (Non-governmental organizations) male
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750
Source link